{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:31:59Z","timestamp":1794958319456,"version":"4.9.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lanepe.2026.101807","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:20:28Z","timestamp":1786450828000},"page":"101807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual, and other men who have sex with men in Spain"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6329-0311","authenticated-orcid":false,"given":"Philip Erick","family":"Wikman-Jorgensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Iniesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ruiz-Alguer\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Perez-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9125-7706","authenticated-orcid":false,"given":"Jara","family":"Llenas-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101807_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2026.101807_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3389\/fphar.2018.00799","article-title":"Efficacy and safety of oral TDF-based pre-exposure prophylaxis for men who have sex with men: a systematic review and meta-analysis","volume":"9","author":"Huang","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lanepe.2026.101807_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAI.0000000000001129","article-title":"Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation","volume":"73","author":"Marcus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.lanepe.2026.101807_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"Preexposure prophylaxis for HIV infection integrated with Municipal- and community-based sexual health services","volume":"176","author":"Liu","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.lanepe.2026.101807_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26107","article-title":"Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition","volume":"26","author":"Lorenzetti","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.lanepe.2026.101807_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101807_bib8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"Kelley","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101807_bib9","author":"Aguirrebengoa"},{"key":"10.1016\/j.lanepe.2026.101807_bib11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.eimc.2024.12.023","article-title":"Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men","volume":"43","author":"Wikman-Jorgensen","year":"2025","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.lanepe.2026.101807_bib13","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1016\/S2352-3018(24)00239-X","article-title":"Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and Southern Africa: a modelling analysis","volume":"11","author":"Wu","year":"2024","journal-title":"Lancet HIV"},{"key":"10.1016\/j.lanepe.2026.101807_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.lanepe.2026.101807_bib15","first-page":"28826","article-title":"Ley 14\/2007, de 3 de Julio, de Investigaci\u00f3n biom\u00e9dica","volume":"159","year":"2007","journal-title":"Bolet\u00edn Oficial del Estado"},{"key":"10.1016\/j.lanepe.2026.101807_bib19","author":"Hernando"},{"key":"10.1016\/j.lanepe.2026.101807_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0272989X02238300","article-title":"A meta-analysis of utility estimates for HIV\/AIDS","volume":"22","author":"Tengs","year":"2002","journal-title":"Med Decis Making"},{"key":"10.1016\/j.lanepe.2026.101807_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206755","article-title":"Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain","volume":"13","author":"Kasaie","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.lanepe.2026.101807_bib26","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1097\/QAD.0000000000004232","article-title":"Effects of test-and-treat versus preexposure prophylaxis on elimination of HIV transmission: analysis of 24 HIV prevention trials","volume":"39","author":"Garratt","year":"2025","journal-title":"AIDS"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266677622600219X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266677622600219X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:08:26Z","timestamp":1792768106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266677622600219X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":16,"alternative-id":["S266677622600219X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101807","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual, and other men who have sex with men in Spain","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101807"}}